To advance clinical translation, we next tested the effects of an FDA-approved 5HT2A inverse agonist (pimavanserin) on glioma proliferation rates and overall survival in models of DMG in the ventral pons or GBM in the cortex without optogenetic stimulation (Fig. 4L). This evidence concerns the gene HTR2A and glioblastoma.